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Tumor macrophages have an important role in cancer pathogenesis. Within aggressive tumors such as glioblastoma (GBM), melanoma, and lung carcinoma, tumorsupportive macrophages have been found to inhibit the antitumor immune response and promote angiogenesis, tumor growth, and therapy resistance. [1] [2] [3] [4] [5] These tumor-supportive macrophages, known as M2 macrophages, are one phenotype on the phenotypic spectrum that macrophages acquire through microenvironmental signaling. [6] [7] [8] M2 macrophages provide local immune suppression, promote a T helper cell (Th) type 2 response, and are involved in parasite clearance, tissue remodeling, and tumor development through production of interleukin (IL)-1RA, IL-10, vascular endothelial growth factor, and transforming growth factor-β, regulated by interferon regulatory factor 4 (IRF4)-signal transducer and activator of transcription 6 (STAT6) pathway. 7, [9] [10] [11] [12] [13] At the opposite end of the spectrum are M1 macrophages with pro-inflammatory properties. These macrophages kill intracellular pathogens and promote a Th1 response, as well as mediate an antitumor immune response by pro-inflammatory cytokine production such as tumor necrosis factor alpha (TNF-α), IL-1B, IL-6, IL-8, IL-12, and IL-23, regulated by the nuclear factorkappaB (NF-κβ) pathway. 7, 14, 15 However, the M1 and M2 dichotomy used to simplify description of polarized macrophages in vitro are phenotypic extremes and therefore do not fully resemble in vivo macrophage phenotypes, which show less pronounced M1/M2 phenotypes and functional plasticity. 7 Both phenotypes are primarily regulated through IRF4 (M2) and IRF5 (M1) competing for the myeloid differentiation primary response gene 88 (MyD88) complex involved in Toll-like receptor (TLR) signaling. 16, 17 Therefore, the in vivo phenotype is based on the dominant cytokines, genes, and proteins expressed.
Within GBM, a malignant brain tumor known for its heterogeneity and dismal prognosis, M2-like macrophages are abundant and their presence is negatively correlated with patients' progression-free survival and overall survival. [18] [19] [20] Moreover, in vitro models have shown that glioma stem-like cells (GSCs), 21 the current gold standard for glioma cultures, induce the M2 phenotype in macrophages, suppressing an immune response and enabling tumor evasion from immune cell clearance. 22, 23 A new and promising treatment for GBM consists of oncolytic viruses (OVs), which combine direct cancer cell lysis with systemic antitumor immunity induction. 24 The oncolytic adenovirus Delta24-RGD, also known as DNX-2401, was designed to replicate selectively in cells harboring retinoblastoma gene or pathway mutations, currently under investigation in clinical phase II trials for GBM. 25 We previously demonstrated that intratumoral injections of this virus in murine GBM leads to increased intratumoral macrophage numbers. 26 Recently Saha et al demonstrated in murine models that tumoral macrophages play a crucial role in herpes simplex oncolytic virotherapy and that the virus shifts the murine GBM macrophage phenotype from M2 to M1, 27 suggesting that OVs can be used as inducers of pro-inflammatory signaling in macrophages and may offer a tool to shift macrophage phenotype in human tumors. 28 As clinical trial material is limited, this OV macrophage modulating effect has thus far not been studied in humans. To elucidate OV effects on behavior and function of human GBM macrophages we investigated macrophage phenotype and function upon Delta24-RGD treatment in vitro and in patients, including extensive analysis of GBM resection material from a Delta24-RGD-treated patient and cerebrospinal fluid (CSF) from 18 Delta24-RGD-treated patients. Together, our results demonstrate that Delta24-RGD therapy changes the GBM macrophage phenotype from protumoral M2 toward the antitumoral and pro-inflammatory M1 phenotype, thereby disabling a major tumor-maintaining mechanism.
Materials and Methods
Patient Material
Tumor tissue was obtained from GBM patients undergoing a routine tumor resection procedure at primary diagnosis. These tumor samples were either used to establish GSC cultures, according to Balvers et al, 29 or used for flow cytometric analysis. Tumor tissue was also obtained from 2 patients enrolled in a clinical phase I/II study testing convection-enhanced delivery of Delta24-RGD virus (ClinicalTrials.gov: NCT01582516). This was an open-label nonrandomized 2-center study for which 19 patients were recruited. From Patients 12 and 16, tumor resection material was obtained at 8 weeks and 26 months, respectively, after receiving loco-regional infusion of 10^10 infectious viral particles. Stored material from Patient 12 was used for cryosectioning and immunohistochemistry, while tissue from Patient 16 was directly dissociated and analyzed by flow cytometry as described below.
CSF from 18 clinical trial patients was obtained through a subcutaneous ventricular catheter system enabling repetitive CSF sampling. Within one hour, cells and debris were removed and CSF was stored at −80°C. This trial was approved by the Central Committee on Research Involving
Importance of the study
Tumor macrophages are important for tumor progression and maintenance. This has led to a search for macrophage modulating therapeutic tools. Here we combine human in vitro and patient studies to demonstrate the glioblastoma macrophage modulating effect of the oncolytic adenovirus Delta24-RGD, leading to a pro-inflammatory and tumor-detrimental microenvironment. To our knowledge, this is the first study to describe an oncolytic virus-induced prolonged M2 to M1 tumor macrophage phenotype shift in human GBM patients. Since this shift disables a major GBM-maintaining mechanism and disrupts indirect local GBM-induced immune suppression, this effect may play a significant role in oncolytic virotherapy in humans. 
Viruses
The conditionally replicating human adenoviruses Delta24-RGD and its derivative encoding green fluorescent protein (GFP) under the adenovirus major late promoter, Delta24-RGD-GFP, were described previously. 30, 31 The replicationdeficient E1 deleted adenovirus expressing luciferase under the cytomegalovirus promoter, Ad.Luc.RGD, has been described previously. 32 
Immunohistochemistry
Fresh frozen tumor sample cryosections were fixed in acetone before Protein Block (Dako) was added, before staining with cluster of differentiation (CD)68 (clone KP-1, Dako), fluorescein isothiocyanate (FITC)-conjugated anti-hexon (Santa Cruz Biotechnology) and Alexa Fluor 568 rabbit anti-mouse immunoglobulin G (heavy + light chain) (Life Technologies Europe). Slides were mounted with 4′,6′-diamidino-2-phenylindole (Vectashield, Vector Laboratories) and imaged on a Leica DMRB microscope.
Macrophage Culture and Polarization
Human CD14-positive monocytes were isolated by CD14 MicroBeads (Miltenyi) from healthy donor buffy coats (project #NVT 0084.02, Sanquin). Monocytes were cultured for 4 days with Iscove's modified Dulbecco's medium (IMDM) (Thermo Fisher Scientific) containing 10% heat-inactivated fetal calf serum (Life Technologies), 5% penicillin/streptomycin (Life Technologies), and 5 ng/mL macrophage colony-stimulating factor (M-CSF) (R&D Systems). Then, IL-4, interferon (IFN)-γ (both 50 ng/mL, R&D Systems), or phosphate buffered saline (PBS) was added for 24 h.
GSCs were pre-infected at multiplicity of infection (MOI) 25 Delta24-RGD for 24 h then washed with PBS twice prior to being added to macrophages cultured and polarized using IL-4 (M2) as described above. All experiments were performed at least twice and in duplicate. Supernatants were stored at −20°C and cells were harvested for flow cytometry or mRNA isolation. Cytochalasin D (SigmaAldrich) was added to the appropriate cultures at 10 µM, 5 min prior to addition of infected GSCs.
Viral Infectivity and Replication Assay
Ad.Luc.RGD was added at MOI 25 to cultured M1 and M2 macrophages. After 24 h, intracellular luciferase was measured using the Promega Luciferase Assay according to the manufacturer's instructions. Delta24-RGD-GFP was added at MOI 25 and macrophages were followed by time-lapse imaging with an IncuCyte system (Essen Bioscience).
Flow Cytometry
Scraped monolayer cells or dissociated tumor material was washed with with PBS + 0.5% bovine serum albumin before 30 min staining with antibodies (Supplementary Table S1 ). Fix&Perm (Nordic MUbio) was used to fix and intracellularly stain with FITC-conjugated anti-hexon (Santa Cruz Biotechnology). Samples were acquired on a FACSCanto II (BD Biosciences) and analyzed using Infinicyt v1.8 (Cytognos) (see Supplementary Fig. S2 for gating strategy).
Gene Expression Analyses
RNA from cultured macrophages was isolated using the RNeasy mini kit (#74104, Qiagen). Primers and probes (Supplementary Table S1 ) were used to analyze cytokine expression, with the ABL gene as reference. Samples were run for 40 cycles on a 7900 HT Fast Real-Time PCR system (Applied Biosystems).
Cytokine Analysis
Cytokine levels in culture supernatants were measured using the Cytometric Bead Array Human Inflammatory Cytokines Kit (BD Bioscience), according to the manufacturer's instructions with undiluted samples with technical replicates. Data analyses were done using FCAP Array v3.0 software (BD Bioscience).
Patient CSF cytokine levels were analyzed using MSD electrochemiluminescence panels and a SECTOR Imager 6000 Plate Reader according to the manufacturer's instructions. Data were analyzed using MSD Discovery Workbench software (all MSD Mesoscale Discovery).
Conditioned Medium Experiments
Control GSCs and Delta24-RGD-infected GSCs (MOI 25) were cultured for 72 h in 5 ng/mL M-CSF in IMDM (10% fetal calf serum + 5% penicillin/streptomycin). The conditioned media (CM) were stored for up to 3 months at −80°. Thawed samples were added to M0 macrophages cultured as above with PBS. After 72 h, cells were harvested and stained for flow cytometric analyses as above. For Delta24-RGD spiking of control GSCs CM, MOI 25 relative to the monocytes was used. CM was filtered by Amicon Ultra-4 (100 000 molecular weight cutoff) Centrifugal Filter Device (Millipore) at 4000 g for 15 minutes.
Macrophages Cultured in Patients' CSF
CD14+ monocytes were cultured for 4 days in 5 ng/mL M-CSF and IMDM (10% fetal calf serum + 5% penicillin/streptomycin). Fresh medium was mixed (2:1) with patients' CSF and added for 72 h prior to harvesting of cells and flow cytometric analysis.
Statistical Analysis
Statistical analysis was performed with SPSS Statistics 21 (IBM). Missing data points were excluded. Gaussian van den Bossche et al. Virotherapy induces M1 GBM macrophages in humans NeuroOncology datasets were analyzed using one-way ANOVA and if P < 0.05 followed by Tukey's multiple comparison test. NonGaussian distributed paired samples were analyzed using the Wilcoxon signed rank test. Differences were considered statistically significant when P < 0.05.
Results and Discussion
Tumor Macrophages Phagocytize Infected Tumor Cells
Cryosections of recurrent GBM tissue obtained from a Delta24-RGD-treated patient 8 weeks after virus infusion were stained for the macrophage marker CD68 and the adenoviral protein hexon to assess immune cell infiltration and virus-infected tumor cells. CD68-positive cells contained hexon-positive concentrations (Fig. 1A) . We hypothesized that these hexon concentrations may be derived from either viral replication in macrophages or infected tumor cell phagocytosis by macrophages. To investigate this, we infected human macrophages and GSC cultures with the replication-defective adenoviral vector Ad.Luc. RGD. Significantly higher luciferase expression was found in the GSC cultures (ANOVA P = 0.003, Tukey P = 0.032, Fig. 1B ), indicating that macrophages are susceptible to RGD-modified adenovirus infection, albeit to a lesser extent than tumor cells. Infection of GSCs and macrophages with the replication-competent adenovirus Delta24-RGD-GFP revealed abundant GFP expression in the infected GSCs, whereas no GFP was detected in the macrophages, indicating lack of adenoviral replication in macrophages (Fig. 1C and Supplementary Movie S1). The macrophage resistance to wild-type adenovirus replication has been shown previously, 33 and our results demonstrate that also Delta24-RGD is not capable of replicating in these cells.
To evaluate whether the observed hexon positivity in tumor macrophages is caused by phagocytosis, we cultured macrophages with Delta24-RGD, Delta24-RGDinfected human primary GSCs, or control human primary GSCs. Significantly increased amounts of hexon-positive macrophages were observed after 24 h in the co-cultures with Delta24-RGD-infected GSCs but not in co-cultures with Delta24-RGD (P = 0.001) or uninfected GSCs (P = 0.009) (Fig. 1D) . Addition of cytochalasin D, which blocks actin polymerization required for phagocytosis, 34 completely abrogated hexon positivity in macrophages (P = 0.011) (Fig. 1D ). This indicates that the observed hexonpositive macrophages in the resected tumor have most likely acquired this through Delta24-RGD-infected tumor cell phagocytosis.
Phenotype, Cytokine Profile, and Phagocytosis Capacity of In Vitro Polarized Macrophages
Most tumor macrophages are derived from blood monocytes, 35, 36 and their tumor promoting and immunesuppressive M2-like phenotype is induced by the tumor microenvironment. Therefore we used human monocytes to culture macrophages, which were polarized by IFN-γ (M1) or IL-4 (M2), or PBS (M0) as a control. To validate the macrophage phenotypes, differential expression of polarization markers CD64, CD192 (C-C chemokine receptor type 2), TLR4, CD163, and CD206 was assessed after 24 h. The selected markers were based on extensive in vitro immunophenotyping experiments. 37 Macrophages cultured with IFN-γ increased expression of the M1 markers CD64, CD192, and TLR4 and downregulated CD163 and CD206, whereas macrophages cultured with IL-4 increased expression of CD163 and CD206 and downregulated CD64, confirming appropriate macrophage polarization ( Fig. 2A) . Gene expression analysis showed that 24 h of M1 polarization significantly upregulated TNFA (P < 0.005), IL6 (P < 0.005), IFNG (P < 0.005), IRF4 (P < 0.01), and IRF5 (P < 0.05), and downregulated IL10 (P < 0.05) compared with M0, whereas M2 macrophages significantly upregulated IRF4 (P < 0.01) and IRF5 (P < 0.05). M2 macrophages had significantly lower TNFA (P < 0.001), IL6 (P < 0.001), and IFNG (P < 0.001) expression compared with M1 (Fig. 2B) . Additionally, the supernatant cytokine profiles of the different phenotypes revealed increased levels of TNF-α (P < 0.01) and IL-6 (P < 0.01) in the M1 cultures. IL-8 was significantly decreased (P < 0.001) in the M2 culture. IL-10, IL-1β, and IL-12p70 levels did not significantly differ between phenotypes (Fig. 2C) .
Co-cultures of the different macrophage phenotypes with Delta24-RGD-infected GSCs showed that M1 macrophages were more efficient in phagocytizing infected GSCs than the other phenotypes (P < 0.05) (Fig. 2D) . Addition of the virus only to these cultures revealed no hexon-positive macrophages in any of the phenotypes up (B-D) Data represent at least 2 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001 (one-way ANOVA, Tukey post-hoc test).
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Delta24-RGD Shifts Macrophages from M2 to M1 Phenotype
As GBMs contain mostly protumoral M2-like macrophages 19 and viruses can induce a pro-inflammatory microenvironment, 27,28,38 we investigated whether Delta24-RGD was capable of shifting the phenotype of human macrophages from M2 to M1. M2 macrophages cultured with either Delta24-RGD or Delta24-RGD-infected GSCs for 72 h demonstrated upregulation of CD64 and downregulation of CD163, indicative of an immunophenotypic shift toward M1. This shift did not occur when M2 macrophages were cultured with uninfected GSCs (Fig. 3A) .
Furthermore, M2 macrophages cultured with Delta24-RGD for 72 h demonstrated significant upregulation of TNFA (P = 0.003), IL6 (P < 0.001), IL10 (P = 0.004), IFNG (P < 0.001), and IRF5 mRNA (P = 0.027) compared with cultures of M2 macrophages, while IRF4 was slightly downregulated (P = 0.003). A comparable change in gene expression was observed in the co-cultures with virusinfected GSCs compared with uninfected GSCs, where TNFA (P = 0.045), IL10 (P = 0.004), IFNG (P = 0.003), IRF4 (P < 0.001), and IRF5 (P = 0.003) were increased. Only the IL6 expression was decreased by infected GSCs compared with uninfected GSCs (P = 0.07) (Fig. 3B) .
Cytokine levels in culture supernatants confirmed the gene expression results. TNF-α (P = 0.045), IL-10 (P = 0.04), IL-1β (P = 0.013), and IL-12p70 (P = 0.025) were increased in co-cultures with virus-infected GSCs. Contrary to the gene expression data, IL-6 production was significantly increased in conditions with GSCs compared with the conditions without GSCs (P = 0.003), but not by the virus alone (P = 0.68) (Fig. 3C) . IL-6, under regulation of the M1-associated NF-κβ-pathway, 39 has been ambiguously described as both tumor promoting as well as an initiator of antitumor immunity. 40 Interestingly, among the evaluated cytokines, only IL-12p70 was increased with infected GSCs and not with Delta24-RGD alone, suggesting a combined effect of the presence of tumor cells and virus, leading to production of this anti-angiogenic and Th1-lymphocyte activating cytokine. 41 The infected tumor cells themselves were not the source of this increase, since they stopped producing several of the evaluated cytokines, as shown by Supplementary  Fig. S3 ). Altogether, a full phenotypic shift with complete loss of M2 traits was not observed, fitting with the notion that the defined M1 and M2 phenotypes are extremes on the polarization spectrum which cannot be obtained under physiological conditions. This is attributed to the complex changes necessary to shift phenotype as well as the many factors influencing macrophage heterogeneity in glioma. 6 However, our results do demonstrate that in vitro Delta24-RGD shifts human macrophages from a more tumor-supportive toward a tumor-detrimental phenotype.
In the Tumor Environment Both GSC-Derived Factors and the Presence of Viral Particles Are Required to Induce M1 Polarization
To study whether in macrophage-tumor cell interactions (eg, phagocytosis), soluble factors or viral particles induce the macrophage phenotypic shift, we tested several conditions on unpolarized (M0) macrophages to allow the evaluation of small effects. Addition of conditioned medium from GSCs (GSC CM) to M0 macrophages significantly decreased CD64 expression (P < 0.001), whereas CD163 was not significantly affected, confirming the M2 polarizing effects of the tumor environment. CM from Delta24-RGD-infected GSCs led to increased M1 markers CD64 (P < 0.001) and CD192 expression (P = 0.005) compared with control GSC CM, whereas no significant effect was observed on CD163 and CD206 (Fig. 3D) . This indicates that soluble factors from OV-infected GSCs can induce a phenotypic shift toward M1 without direct contact between macrophages and GSCs (eg, phagocytosis).
Whether Delta24-RGD particles in the tumor microenvironment exert these M1 polarizing effects was evaluated by spiking virus into GSC CM. Surprisingly, this did not alter CD64 and CD192 M1 marker expression compared with GSC CM, but did lead to decreased CD163 and CD206 M2 marker expression. Indeed, compared with Delta24-RGD-infected GSC CM, all markers remained lower. Together, these results suggest that local tumor cells need to be infected by the virus to allow M1 marker upregulation, and the viral particles in the tumor environment contribute to M2 marker downregulation, together inducing M1 polarization (Fig. 3D) .
To gain insight into the nature of the secreted factors from infected cells that are involved in the M1 polarization, the Delta24-RGD-infected GSC CM was filtered using a 100 kD filter, which retains large structures, such as adenoviruses and extracellular vesicles, and allows small secreted and/or soluble factors such as cytokines to pass. This filtered CM did not induce the phenotypic shift observed with Delta24-RGD-infected GSC CM. The M1 marker increase induced by Delta24-RGD-infected GSC CM was not observed, while a decrease in the M2 markers CD163 and CD206 (P < 0.05) was observed. The latter is not unexpected, as it has been shown that larger-sized GSC-derived vesicles mediate M2 polarizing effects, 21 although we cannot exclude that small molecules produced by the virus-infected cells also contribute to M1 polarization (Fig. 3D) . We therefore conclude that within the tumor microenvironment, OV delivery leads to a phenotypic switch through the concerted action of a change in factors produced by OV-infected GSCs and the presence of viral particles, together contributing to an M1 macrophage phenotypic switch.
Delta24-RGD Treatment Markedly Changes Cytokine Profile in Patients' CSF
Unique CSF samples from patients enrolled in the phase I/II Delta24-RGD clinical trial at our institute provided the opportunity to explore the clinical relevance of our in vitro data. Poli et al previously showed that a tumor-detrimental microenvironment in mice can be detected through analysis of CSF cytokine levels. 5 Indeed, analysis of postDelta24-RGD treatment CSF samples revealed significantly increased levels of TNF-α (P = 0.002), IL-6 (P = 0.001), and IFN-γ (P = 0.005) (P < 0.01) (Fig. 4A) . Additionally, IL-10 levels were also increased, corresponding with the virus-induced gene expression and cytokine profiles found in our in vitro experiments. This demonstrates that Delta24-RGD therapy in humans alters the tumor microenvironment toward a more pro-inflammatory state.
Patients' CSF Alters Macrophage Phenotypes
To assess whether the detected microenvironmental changes not only are hallmarks but also induce the macrophage phenotypic shift, we selected 3 CSF samples with a marked change in cytokine levels ( Fig. 4A ; full squares) and 3 samples with a limited change in cytokine levels ( Fig. 4A; open triangles) . Macrophages cultured for 72 h in markedly changed CSF revealed significant CD64 upregulation (Fig. 4B) . Furthermore CD192, CD163, and CD206 were slightly upregulated with the posttherapy CSF. Interestingly, macrophages co-cultured with CSF samples with limitedly changed cytokine levels did not reveal changes in marker expression (Fig. 4B) . This heterogeneity in macrophage van den Bossche et al. Virotherapy induces M1 GBM macrophages in humans NeuroOncology response suggests that the conditions required to induce the immunophenotypic shift are present in some patients' CSF, whereas in others it is not, a phenomenon that may be related to therapeutic efficacy of OV treatment.
Patients' GBM-Macrophage Immunophenotype Shifts upon Delta24-RGD Treatment
Direct immunophenotypic analysis of tumor macrophages from OV-treated GBM patients is rarely possible. Only a limited number of clinical trials have been performed and secondary resections are uncommon. In the trial at our institute, a patient who had received Delta24-RGD treatment 26 months earlier underwent a second tumor resection due to recurrence. Considering the normal time to progression in recurrent GBM (mean 6.2 mo 42 ), this was an exceptionally long progression-free survival. The resected tumor tissue was immunophenotyped and compared with 5 untreated GBMs. As GBM is notorious for intratumoral heterogeneity, the sampled tumor cannot represent the entire tumor, limiting result interpretation. Nevertheless, intratumoral macrophages in the virus-treated GBM demonstrated increased CD192 (P = 0.002), TLR4 (P = 0.008), and CD64 expression. Furthermore, we found decreased CD206 expression and increased levels of CD163 compared with the majority of untreated GBMs (Fig. 4C) . Although CD163 was not decreased, as would be expected for an M1 phenotype, the other phenotype markers suggest OV treatment induced pro-inflammatory effects and prolonged phenotypic changes in tumor-associated macrophages. Whether this phenotypic shift is related to the patient's delayed recurrence needs to be investigated in future studies.
The analyses of patient material and our in vitro experiments reveal that under the influence of Delta24-RGD, human (tumor) macrophages change phenotype, thereby modifying the microenvironment toward pro-inflammatory and antitumoral. Although the gene expression, immunophenotype, and cytokine profiles showed that M2 traits were not completely lost, M1 traits became dominant. This lack of a clear boundary between M1 and M2 macrophages in patient-derived material 8 complicates result interpretation; (Fig. 5C-E) . 16, 17, 40, 41 Unfortunately, the limited availability of Delta24-RGDtreated patient material precluded more extensive analysis using larger panels of genes, markers, or timepoints, thereby limiting clinical effect evaluation of the phenotypic shift. In vivo studies in mice, however, may also have limited translational value with regard to macrophage plasticity as murine monocytes/macrophages differ from those in humans. 44 More insight into the effect of phenotypic shifts on tumor cell clearing or antigen presentation upon OV therapy therefore requires further immune monitoring studies in clinical trials. 
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Taken together, we have shown that the antitumor effect of Delta24-RGD therapy is not merely restricted to oncolysis and the induction of a T cell-mediated antitumor response, but local macrophages also gain antitumoral properties. Our studies show that OV therapy may offer the highly sought after tool to modulate tumor-supportive M2 macrophages into antitumoral M1 macrophages in humans, providing a new therapeutic approach to change the tumor microenvironment and possibly improve patient survival. 19, 20, 45 
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